NeuroSense initiated with a Buy at Alliance Global Partners

Alliance Global Partners analyst James Molloy initiated coverage of NeuroSense with a Buy rating and $7.50 price target. The firm notes that its price target is based primarily on expectations for NeuroSense’s PrimeC, a fixed-dose combination of ciprofloxacin and celecoxib, for treatment of Amyotrophic Lateral Sclerosis, or ALS, also called Lou Gehrig’s Disease. PrimeC is currently in the Phase 2b PARADIGM trial of PrimeC in ALS, which is expected to have topline results announced in Q4 and be followed by a pivotal trial in the same indication, possibly in 2024, the analyst tells investors.